Cogstate Selected as Preferred Provider to Lilly’s Alzheimer’s Disease Platform
May 17, 2017
Company to Deliver Novel Solutions to Ensure High-quality Neuropsychological Measures in Clinical Trials
New Haven, CT – May 17, 2017: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced it has been chosen as the preferred provider to the global healthcare leader, Eli Lilly and Company, to support their Alzheimer’s disease platform with solutions to ensure high-quality neuropsychological outcome measures in clinical trials. Cogstate and Lilly will deploy an innovative program to improve the way that research sites train and collect endpoint data across Lilly’s portfolio of Alzheimer’s disease studies.
Underpinned by leading technology, Cogstate has brought together scientific experts with learning experts to create a novel, integrated program that drives efficiencies in rater training and certification, electronic clinical outcome assessment (eCOA) data capture, and risk-based central monitoring.
“We are excited to partner with Lilly to realize their vision for a portfolio-wide approach to endpoint quality assurance that reduces cycle times and lessens the burden on research sites,” commented George Hunnewell, Chief Operating Officer for Cogstate. “By more efficiently and effectively preparing sites to administer neuropsychological assessments across all of Lilly’s Alzheimer’s studies, we dramatically improve the research experience for clinicians and patients while also ensuring greater reliability of the outcome measures.”
Cogstate has supported more than 90 Alzheimer’s disease studies across academic and clinical research with expertise and solutions that help guide decision-making for cognitive safety and efficacy.
Cogstate Ltd (ASX:CGS) is a leading cognitive science company dedicated to optimizing the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides expert support and eCOA for neuropsychological and functional assessments and is a pioneer in commercializing rapid, reliable and highly sensitive computerised cognitive tests. Cogstate customers include the world’s leading biopharmaceutical companies; military and elite sporting organizations; physicians and patients; renowned academic institutions and public-private partnerships. For more information visit www.cogstate.com.
Media Contact: Rachel Colite | Tel: +1 203 773 5010 | Email: email@example.com